GLP-1s and the Executive: What Ozempic-Class Drugs Actually Mean for High Performers

At some point in the last two years, every executive peer group started having the same conversation, usually in a lowered voice: who is on it, how much they have lost, and whether it is cheating. GLP-1 receptor agonists, the drug class behind Ozempic, Wegovy, Mounjaro, and Zepbound, have gone from a diabetes medication to the most discussed intervention in executive health. I have coached clients through starting them, staying on them, and coming off them, and the gap between the dinner-party version of this conversation and the actual science is enormous.

This article is the version I give clients: what these drugs genuinely do well, the real risks that get glossed over, the muscle-loss problem that should concern every high performer over 40, and how to think about GLP-1s as one tool inside a system rather than a substitute for one. If you have followed the work on metabolic health and visceral fat and executive longevity, this is the pharmacology chapter of that same story.

What GLP-1 Drugs Actually Do

GLP-1 is a hormone your gut releases after eating. It tells your pancreas to release insulin, slows how fast your stomach empties, and signals satiety to your brain. The medications are synthetic versions that last far longer than the natural hormone, which is why a weekly injection can blunt appetite around the clock.

The effects that matter for a high performer:

• Appetite and food noise. The most reported effect is not weight loss itself but the quieting of constant background thoughts about food. Many executives describe it as getting back the mental bandwidth that snacking, cravings, and meal decisions were consuming.
• Blood sugar regulation. These drugs were built for type 2 diabetes, and they smooth glucose excursions dramatically, the same variable tracked in continuous glucose monitors and central to blood sugar and executive focus.
• Cardiovascular outcomes. Large trials show meaningful reductions in major cardiovascular events in high-risk populations, which connects directly to the risk picture in ApoB and heart health.
• Visceral fat reduction. Weight lost on GLP-1s includes a disproportionate share of the dangerous fat around the organs, the exact target discussed in the visceral fat article.

In the major trials, average weight loss runs around 15 percent of body weight on semaglutide and over 20 percent on tirzepatide. Those are numbers no lifestyle program matches at population scale, and pretending otherwise is not honest coaching.

The Part Nobody Puts in the Ad: You Lose Muscle Too

Here is the finding that should stop every executive over 40 cold: a substantial fraction of the weight lost on GLP-1s is lean mass, not fat. Depending on the study and how it is measured, roughly 25 to 40 percent of the pounds lost can be muscle and other lean tissue. For a 50-year-old executive, that is not a cosmetic footnote. Muscle is your metabolic engine, your glucose sink, your fall protection, and your longevity insurance, the entire thesis of strength training after 40 and protein and muscle longevity.

Losing 30 pounds where 10 of them are muscle can leave you lighter on the scale and metabolically worse off: lower resting energy expenditure, weaker, and set up for rapid fat regain if the drug stops. This is the pattern behind the term "skinny fat," and it is the single most common failure mode I see in executives who start these medications without a plan.

The good news is that this is largely preventable. The research and clinical experience both point to the same two levers: resistance training and protein. Clients who lift two to three times per week and hit a high daily protein target preserve dramatically more lean mass than those who simply eat less. The drug changes how much you eat; it does not decide what you keep. You do.

The Other Honest Trade-Offs

Muscle loss gets the least airtime, but a full accounting includes more:

• Gastrointestinal side effects. Nausea, reflux, constipation, and occasionally vomiting are common, especially during dose escalation. Most fade, but they are real, and they interact with the gut territory covered in gut health.
• Regain on discontinuation. Trial data shows that when people stop the medication, most regain a large share of the weight within a year unless their habits have genuinely changed. The drug is a lever, not a cure. This is why the identity and systems work in identity-based health change matters more on a GLP-1, not less.
• Nutritional adequacy. Eating far less food means far less room for error on protein, fiber, and micronutrients. The principles in fiber and nutrition fundamentals become non-negotiable when total intake drops.
• Cost and access. These are expensive medications with spotty insurance coverage for weight loss, and supply has been unstable. Any plan that depends on a drug you may not be able to get is a fragile plan.
• Rare but serious risks. Pancreatitis, gallbladder issues, and a thyroid tumor warning from animal studies are on the label. These are conversations for your physician, not your group chat.

Who These Drugs Are Actually For

My honest read, after watching this play out across clients: GLP-1s are a legitimate medical tool for people carrying significant excess weight, especially with metabolic dysfunction, prediabetes, or cardiovascular risk, who have not succeeded with lifestyle change alone. That describes a lot of executives, and there is no virtue in struggling without a tool that works.

They are a poor fit as a cosmetic shortcut for someone who wants to drop ten pounds for a reunion, as a substitute for ever learning to eat well, or as a solo intervention with no training, no protein strategy, and no plan for what happens when the prescription ends. The question is never "should I take the drug." It is "what system does the drug plug into." That is the same frame as why most health programs fail high achievers: tools fail without systems around them.

The Protocol: If You and Your Doctor Decide on a GLP-1

This is the framework I use with clients who, in consultation with their physician, start one of these medications. None of it is optional if you want the benefit without the damage.

1. Lift before you start, and never stop

Resistance training two to three times per week is the single most important protective behavior on a GLP-1. You are in a deficit and your body is deciding what tissue to burn; training is the signal that tells it to keep the muscle. If you have never lifted, start now with the basics from strength training after 40, not after the weight comes off.

2. Anchor protein first

When appetite is blunted, whatever you do eat has to count. Build every meal around a protein anchor before anything else, targeting roughly 0.7 to 1 gram per pound of goal body weight across the day, per the framework in protein and muscle longevity. On a suppressed appetite, protein is the first thing people under-eat and the last thing they can afford to.

3. Measure body composition, not just the scale

A scale cannot tell fat loss from muscle loss. Get a baseline DEXA scan or a quality bioimpedance measurement before starting, and recheck every three to six months. If lean mass is sliding, that is a signal to increase protein and training, not to celebrate a lower number. Treat it like the biomarker tracking in executive bloodwork and biomarkers: the data steers the plan.

4. Keep the habits running underneath

The drug lowers the volume on appetite, which makes it the best window you will ever get to install the habits that have to survive without it: meal structure, walking after meals, metabolic flexibility, sleep, and training. Use the quiet to build the system, following the habit logic in willpower versus habits. The people who keep the weight off after stopping are the ones who used the medication period as construction time.

5. Plan the exit before you need it

Whether you stay on long-term or taper is a medical decision, but either way, have the conversation early about what maintenance looks like. A plan that assumes the drug forever is not a plan; it is a subscription.

The Bottom Line

GLP-1s are neither the miracle the headlines sell nor the cheat the purists claim. They are a powerful lever on appetite and metabolism with a real cost in lean mass if you use them passively, and a real opportunity if you use them as cover to build the training, protein, and habit system that makes the result permanent. The executives who do this well treat the medication like a spotter in the gym: it helps you move the weight, but you still have to lift.

Frequently Asked Questions

Will I lose muscle on a GLP-1 even if I train? Some lean mass loss is common in any significant weight loss, but resistance training plus high protein reduces it dramatically. The clients who lift and eat enough protein keep the vast majority of their muscle; the ones who do neither are the 25 to 40 percent statistics.

Is it cheating? No. It is a medical intervention for a medical problem. The only version of this I push back on is using the drug to avoid ever building the habits, because the regain data says that trade does not work.

What happens when I stop? Appetite signals return, and without changed habits most people regain much of the weight within a year. That is why the habit construction during the medication period is the whole game.

Should I talk to my doctor or a med spa? Your physician, ideally one who will also order labs, discuss body composition, and talk about an exit plan. Be cautious of any provider whose entire plan is a prescription and a follow-up invoice.

Work With Dr. Jason Rannfeldt

Dr. Jason Rannfeldt, also known as Jason Rannfeldt and Jason Lee Rannfeldt, coaches executives and high performers to rebuild health, energy, focus, and identity with systems that fit demanding lives. You can read more of his writing at jasonleerannfeldt.me.

If you want your training, nutrition, and metabolic health built into one coached system, with or without medication in the picture, explore Crush 90 and Thrive 90. Start with a conversation on the contact page, or learn more about my story on the about page.